Research Article
Clinicopathological Profile of Pure Neuroendocrine Neoplasms of the Esophagus: A South Indian Center Experience
Table 2
Baseline characteristics of esophageal NENs.
| Variable | Number (percentage) |
| Age | | <40 years | 5 (11.6%) | 40–60 years | 15 (34.9%) | >60 years | 23 (53.5%) |
| Gender | | Male | 26 (60.5%) | Female | 17 (39.5%) |
| Symptoms | | Dysphagia | 38 (88.3%) | Abdominal/retrosternal pain | 9 (22.5%) | Loss of weight or loss of appetite | 8 (18.6%) | Gastrointestinal bleed | 2 (4.6%) | Carcinoid syndrome | 0 |
| Performance status | | 1/2 | 34 (79%) | 3 | 9 (21%) |
| Esophagus tumor location | | Upper third (15–25 cm from incisor) | 1 (2.3%) | Middle third (25–30 cm from incisor) | 7 (16.3%) | Lower third, GE junction (30–40 cm from incisor) | 35 (81.4%) |
| Mitotic count and Ki-67 index (WHO, [21]) | | G1: <2/10 HPF’s; <2% | 0 | G2: 2–20/10 HPF’s; 3–20% | 7 (16.3%) | G3: >20/10 HPF’s; >20% | 36 (83.7%) |
| Disease stage | | I | 0 | II | 6 (14%) | III | 14 (32.5%) | IV | 23 (53.5%) |
| Treatment received | | STAGE II, III (; 46.5%) | mOS = 18.25 m (2.5–60 m) | Upfront surgery (THE/TTE) CT | mOS = 18.5 m (2.5–60 m) | NACT plus surgery | mOs = 15.25 m | Received Chemo/Oct LAR only | mOS = 12 m (6–30 m) | STAGE IV (; 53.5%) | mOS = 6.5 (1.5–32 m) | Cisplatin + etoposide | mOS = 6.5 m (1.5–32 m) | Octreotide LAR | mOS = 16 m |
| mOS stage II () | 43 m (18–60 m) |
| mOS stage III () | 12.5 m (6–30 m) |
|
|